This content is not available in your region

Valneva says no conclusions to be drawn on its COVID shot from UK booster study

Access to the comments Comments
By Reuters
Valneva says no conclusions to be drawn on its COVID shot from UK booster study
Valneva says no conclusions to be drawn on its COVID shot from UK booster study   -   Copyright  Thomson Reuters 2021

PARIS – French biotech firm Valneva said on Friday that no conclusions should be drawn on the effectiveness of its COVID-19 vaccine candidate, known as VLA2001, from a new British study on booster shots.

The study said COVID-19 vaccines made by Pfizer and Moderna that use mRNA technology provide the biggest boost to antibody levels when given 10-12 weeks after the second dose.

Traders cited the study as the reason behind a fall of up to 24% in Valneva’s shares on Friday.

“The setting in this study leads us to believe that COV-Boost does not allow any conclusions to be reached regarding the use of VLA2001 as a booster in a real-life setting,” Valneva said in an e-mailed statement in response to a Reuters query.

“Valneva believes it is likely that the short interval between the second shot and booster shot could have adversely impacted the results for VLA2001, given that a longer interval is generally required for inactivated vaccines.”